The primary purpose of this trial is to assess the effect of treatment with deferasirox
combined with erythropoietin vs. erythropoietin alone on erythropoiesis in patients with
low- and int-1-risk myelodysplastic syndrome.
The addition of deferasirox to erythropoietin could lead to a potential synergism with the
reduction of reactive oxygen species, through both the NF-kB pathway and the control of free
toxic iron. This may create a better environment in the bone marrow for a better response
with erythropoietin.
This study is designed to test in a prospective way the combination of deferasirox with
erythropoietin in term of their effect on hematopoiesis.
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Novartis Investigative Site, Oran 31000, Algeria; Not yet recruiting
Novartis Investigative Site, Sidi Bel abbes 22000, Algeria; Not yet recruiting
Novartis Investigative Site, Sofia 1756, Bulgaria; Withdrawn
Novartis Investigative Site, Varna 9000, Bulgaria; Withdrawn
Novartis Investigative Site, Jinan 250012, China; Not yet recruiting
Novartis Investigative Site, Berlin 12203, Germany; Recruiting
Novartis Investigative Site, Dresden 01307, Germany; Not yet recruiting
Novartis Investigative Site, Duesseldorf 40225, Germany; Recruiting
Novartis Investigative Site, Rostock 18107, Germany; Recruiting
Novartis Investigative Site, Madrid 28006, Spain; Withdrawn
Novartis Investigative Site, Madrid 28033, Spain; Withdrawn
Novartis Investigative Site, Gothenburg 413 45, Sweden; Recruiting
Novartis Investigative Site, Linköping SE-581 85, Sweden; Recruiting
Novartis Investigative Site, Luleå SE-971 80, Sweden; Recruiting
Novartis Investigative Site, Stockholm SE-118 83, Sweden; Withdrawn
Novartis Investigative Site, Stockholm SE-141 86, Sweden; Recruiting
Novartis Investigative Site, Sundsvall 851 86, Sweden; Recruiting
Novartis Investigative Site, London WC1E 6HX, United Kingdom; Recruiting
Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas 72703, United States; Withdrawn
Hematology Oncology Services of Arkansas SC, Little Rock, Arkansas 72205, United States; Withdrawn
Novartis Investigative Site, Beijing, Beijing 100730, China; Not yet recruiting
Novartis Investigative Site, Vancouver, British Columbia V6Z1Y6, Canada; Recruiting
Novartis Investigative Site, Caba, Buenos Aires C1221ADC, Argentina; Withdrawn
Novartis Investigative Site, La Plata, Buenos Aires B1900AWT, Argentina; Recruiting
Novartis Investigative Site, Cagliari, CA 09100, Italy; Recruiting
Pacific Cancer Medical Center, Inc., Anaheim, California 92801, United States; Completed
Novartis Investigative Site, Cambridge, Cambrigdeshire CB2 0QQ, United Kingdom; Withdrawn
Novartis Investigative Site, Badalona, Catalunya 08916, Spain; Recruiting
Novartis Investigative Site, Girona, Catalunya 17007, Spain; Recruiting
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya 08907, Spain; Recruiting
Novartis Investigative Site, Firenze, FI 50134, Italy; Recruiting
21st Century Oncology SC, Orange Park, Florida 32073, United States; Withdrawn
University of Hawaii Cancer Center SC ICL670A2421, Honolulu, Hawaii 96813, United States; Withdrawn
Novartis Investigative Site, Wuhan, Hubei 430030, China; Not yet recruiting
Rush University Medical Center Rush University, Chicago, Illinois 60612, United States; Withdrawn
Novartis Investigative Site, Nanjing, Jiangsu, China; Not yet recruiting
Novartis Investigative Site, Suzhou, Jiangsu 215006, China; Not yet recruiting
Novartis Investigative Site, Seoul, Korea 135-710, Korea, Republic of; Recruiting
Novartis Investigative Site, Seoul, Korea 138-736, Korea, Republic of; Recruiting
Novartis Investigative Site, Oldham, Lancashire OL1 2JH, United Kingdom; Active, not recruiting
Meridian Health Research Services SC, Neptune, New Jersey 07753, United States; Not yet recruiting
Nancy Lynn Charpek, Email: NCharpek@meridianhealth.com
Aileen Chen, Principal Investigator
Montefiore Medical Center SC ICL670A2421, Bronx, New York 10467-2490, United States; Recruiting
Rana Abdelhamid, Phone: 718-920-6642, Email: raabdelh@montefiore.org
Olga Derman, Principal Investigator
Rochester General Hospital / Lipson Cancer Center SC, Rochester, New York 14621, United States; Recruiting
Brittany Heatherington, Phone: 585-922-4040, Email: Brittany.Heatherington@rochesterregional.org
Pradyumna Phatak, Principal Investigator
Novartis Investigative Site, Hamilton, Ontario L8V 5C2, Canada; Recruiting
Novartis Investigative Site, Toronto, Ontario M4N 3M5, Canada; Recruiting
Novartis Investigative Site, Reggio Calabria, RC 89124, Italy; Recruiting
Novartis Investigative Site, Roma, RM 00161, Italy; Recruiting
St. Francis Hospital, Greenville, South Carolina 29601, United States; Withdrawn
Novartis Investigative Site, Baracaldo, Vizcaya 48903, Spain; Withdrawn
Novartis Investigative Site, Hangzhou, Zhejiang 310003, China; Not yet recruiting